On November 7, 2025 IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, reported it will host an R&D Day on Monday, November 10, 2025 at 8:00 a.m. ET in New York City featuring in-depth discussions with experts including principal investigators leading the Phase 3 OVATION 3 clinical trial and Phase 2 minimal residual disease (MRD) trial of IMNN-001, a novel IL-12 immunotherapy in development for the treatment of women with advanced ovarian cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"This is an opportunity to hear directly from the investigators driving IMNN-001 clinical progress forward—physicians who see firsthand the urgent need for new ovarian cancer treatment options and the potential clinical impact of our novel IMNN-001 immunotherapy," said Stacy R. Lindborg, Ph.D., president and chief executive officer of IMUNON. "The data and insights shared will be consequential for understanding the future of ovarian cancer treatment and how we are leading the effort to bring the first advance in the standard of care that could transform frontline treatment, which has not seen innovation for about 30 years."
The event will include presentations from:
Premal H. Thaker, M.D. (Washington University School of Medicine) – Unmet need and OVATION 2 trial data including survival benefits
Amir A. Jazaeri, M.D. (MD Anderson Cancer Center) – Phase 2 MRD study results and immune activation mechanism overview
Giorgio Paulon, Ph.D. (Berry Consultants, LLC) – Phase 3 trial statistical design and path to approval
Douglas V. Faller, M.D., Ph.D. (IMUNON) – Phase 3 trial enrollment momentum and clinical milestones
(Press release, IMUNON, NOV 7, 2025, View Source [SID1234659636])